EFUDEX-GENERIC
Total Payments
$72,812
Transactions
1
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $72,812 | 1 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $72,812 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| 2014-11 Palefsky ANCHOR | Valeant Pharmaceuticals North America LLC | $72,812 | 1 |
Top Doctors Receiving Payments for EFUDEX-GENERIC
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Internal Medicine | San Francisco, CA | $72,812 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $72,812
- Total Doctors 1
- Transactions 1
About EFUDEX-GENERIC
EFUDEX-GENERIC is a drug associated with $72,812 in payments to 1 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is Valeant Pharmaceuticals North America LLC.
Payment data is available from 2017 to 2017. In 2017, $72,812 was paid across 1 transactions to 1 doctors.
The most common payment nature for EFUDEX-GENERIC is "Unspecified" ($72,812, 100.0% of total).
EFUDEX-GENERIC is associated with 1 research study, including "2014-11 Palefsky ANCHOR" ($72,812).